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Abstract
It has been well documented that microenvironment consisting of stroma affects breast cancer progression. However, the
mechanisms by which cancer cells and fibroblasts, the major cell type in stroma, interact with each other during tumor
development remains to be elucidated. Here, we show that the human cancer-associated fibroblasts (CAFs) had higher
activity in enhancing breast tumorigenecity compared to the normal tissue-associated fibroblasts (NAFs) isolated from the
same patients. The expression level of hepatocyte growth factor (HGF) in these fibroblasts was positively correlated with
their ability to enhance breast tumorigenesis in mice. Deprivation of HGF using a neutralizing antibody reduced CAF-
mediated colony formation of human breast cancer cells, indicating that CAFs enhanced cancer cell colony formation
mainly through HGF secretion. Co-culture with human breast cancer MDA-MB-468 cells in a transwell system enhanced
NAFs to secret HGF as well as promote tumorigenecity. The newly gained ability of these ‘‘educated’’ NAFs became
irreversible after continuing this process till fourth passage. These results suggested that breast cancer cells could alter the
nature of its surrounding fibroblasts to secrete HGF to support its own progression through paracrine signaling.
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Introduction
During tumor progression, the stroma surrounding cancer cells
has been found to undergo phenotypic and epigenetic changes
[1,2,3,4,5]. The tumor stroma consists of a base membrane,
extracellular matrix, blood vasculature, inflammatory cells and
fibroblasts, which were all shown to contribute to cancer
development [1,6,7]. Among these components, fibroblasts were
found to have a predominant role in cancer progression [8,9].
Fibroblasts in the breast tumor stroma were proposed to be
‘‘activated’’ to assist tumor development. Recent studies revealed
that the primary cancer-associated fibroblasts (CAFs) derived from
invasive breast carcinomas had greater potential to promote tumor
growth and angiogenesis than the normal tissue-associated
fibroblasts (NAFs) derived from non-cancer breast regions of the
same patients or from reduction of mammoplasty tissues [10].
These results suggested that cancer cells may alter ability of
neighboring fibroblasts to promote tumorigenesis. In addition,
normal fibroblasts have also been shown to acquire oncogenic
promoting activity by exposure to carcinogens, irradiation, wound
healing and senescence [6]. These results indicated that under
certain conditions the property of fibroblasts would be changed to
assist tumor progression. However, the mechanism that makes
these fibroblasts activated is not yet fully understood.
The communication between surrounding fibroblasts and
cancer cells may go through cytokines. Previous reports revealed
that gene expression profiles of myofibroblasts isolated from in situ
and invasive breast carcinomas differed from those derived from
normal breast tissues [11]. The differential expression included
genes encoding secreted proteins and receptors, indicating that
there are paracrine interactions between cancer cells and stromal
myofibroblasts. Stromal cell-derived factor 1 (SDF-1/CXCL12) is
one of the prominent chemokines secreted by stromal myofibro-
blasts. SDF-1 has been reported to be highly expressed in CAFs to
promote tumorigenesis compared to NAFs [10]. In addition,
hepatocyte growth factor (HGF) is an important fibroblast-
secreted protein that mediates development and progression of
cancers [12,13]. HGF is mainly secreted from fibroblasts, whereas
its receptor, c-Met receptor tyrosine kinase, is primarily expressed
in epithelial cancer cells [14]. These results suggested that
fibroblasts contribute to tumor development through secreting
certain cytokine factors. However, whether the heterogeneous
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cancer cells remains to be determined.
In this communication, we have compared five pairs of CAFs
and NAFs derived from breast cancer patients. We found that
NAFs have significantly lower tumor promoting activity compared
to CAFs. In contrast to previous report, HGF, instead of SDF-1, is
elevated in all CAFs. Deprivation of HGF by neutralizing with
anti-HGF antibodies diminished the tumor promoting activity of
CAFs. These results suggested that HGF may be a general
contributing factor secreted from CAFs to promote tumorigenesis.
Importantly, HGF expression and the tumor promoting activity of
NAFs can be induced and fixed to similar levels as those of CAFs
by long term co-culturing NAFs with breast cancer MDA-MB-468
cells in a transwell system. These finding provides evidence that
breast cancer cells could induce alteration of fibroblasts via
paracrine pathway to enhance fibroblast’s ability to secrete HGF
and promote tumorigenesis.
Results
Breast cancer-associated fibroblasts have higher ability to
enhance breast tumorigenesis than normal tissue-
associated fibroblasts
To compare the differential effects of CAFs and NAFs on breast
tumorigenesis, we isolated fibroblasts of human breast cancer
tissue and adjacent normal breast tissue from the same patients.
These primary fibroblasts were grown to 100% confluent in
culture and then evaluated for their abilities to promote cancer
cells to form colony in soft agar. Using this soft agar colony
formation system, we compared the effects of five pairs of CAFs
and NAFs on the MDA-MB-468 cell colony formation in nutrition
restricted medium, in which MDA-MB-468 cells could not form
colonies in the absence of fibroblasts. Although both CAFs and
NAFs were able to support MDA-MB-468 cells to form colonies,
significantly more colonies (about 30–50% more) were formed
when cells were co-cultured with CAFs (with the average about
650 colonies) compared to NAFs co-culture (about 490 colonies)
(Figure 1A and 1B). Similar results were observed using another
breast cancer cell line, SK-BR-3 (Figure 1C and 1D). Taken
together, these results indicated that CAFs, compared to NAFs,
significantly enhanced colony formation of these breast cancer
cells.
Next, we examined whether CAFs and NAFs differentially
support tumor growth in vivo using immunocompromised NOD/
SCID mice. Fibroblasts from 100% confluent culture were mixed
with MDA-MB-468 cells at 5:1 ratio and injected into the fat pads
of the NOD/SCID mice. CAF #199C significantly enhanced the
tumor growth by 2-3-fold compared to NAF #200N and the
control (no fibroblasts) (Figure 1E). CAFs or NAFs alone did not
lead to tumor formation. The tumors were composed of lots of
MDA-MB-468 cells and very few human fibroblasts three weeks
after injection. Thus, CAFs possessed higher ability to enhance the
breast tumorigenesis in vivo at the initial stage than NAFs.
Identification of secreted factors from CAFs and NAFs
that affect breast tumorigenesis
To identify the factors that contribute to or inhibit tumorigen-
esis, we compared the profiles of secreted proteins from CAF
#199C and NAF #200N using the cytokine/growth factor
antibody arrays. The results showed that hepatocyte growth factor
(HGF) and tissue inhibitor of metalloproteinases-1 (TIMP-1)
(examined by the array B) were secreted at higher levels from
CAFs compared to NAFs (Figure 2A and Figure S1). In contrast,
granulocyte chemotactic protein-2 (GCP-2; also named CXCL6,
CXC ligand 6) (examined by the array A), insulin-like growth
factor binding protein-3 (IGFBP-3), growth-related oncogene
(GRO; the antibody could recognizes GRO-a, GRO-b and
GRO-c), growth-related oncogene-alpha (GRO-a; also named
CXCL1, CXC ligand 1), epithelial cell-derived neutrophil-
activating peptide-78 (ENA-78; also named CXCL5, CXC ligand
5), granulocyte colony stimulatory factor (GCSF) (the array B) and
latency-associated peptide (LAP) (the array C) were secreted at
lower levels from CAFs compared to NAFs. The levels of
monocyte chemotactic protein-1 (MCP-1; also named CCL2),
insulin-like growth factor binding protein-6 (IGFBP-6) and insulin-
like growth factor-II (IGF-II) were identical from both fibroblasts
and were used as the internal control.
To confirm the results of the cytokine/growth factor antibody
arrays, Western blotting analysis for several growth factors was
carried out. The HGF protein levels in CAFs were higher than
those in NAFs (Figure 2B). The HGF protein levels secreted from
CAFs were also higher than those from NAFs, assessed by enzyme-
linked immunosorbent assay (Figure 2C). These finding were
consistent with the results of the cancer cell colony formation
assays and the tumorigenesis assay in the NOD/SCID mice. The
results of Western blotting analysis also indicated that the levels of
IGFBP-3 in CAFs and NAFs were not correlated to fibroblast-
mediated tumor growth.
The messenger RNA (mRNA) levels of HGF in CAFs and
NAFs were also compared by quantitative real-time RT-PCR
analysis. The results showed that the HGF mRNA levels in CAFs
were higher than NAFs (Figure 2D), indicating that differences in
the HGF protein levels were likely due to alterations in the
mRNA. The mRNA level of SDF-1, which was proposed to play
an essential role in stromal fibroblast-mediated breast tumorigen-
esis [10], was also examined. However, there was no strict
correlation between the mRNA levels of SDF-1 a, b and c
isoforms and the abilities of these fibroblasts to promote breast
tumorigenesis (Figure 2E).
HGF neutralizing antibodies abolished soft agar colony-
promoting effect of CAFs
To test whether HGF directly contributes to the effect on
enhancing breast cancer cells in soft agar colony formation, anti-
HGF antibodies were added to the soft agar medium to neutralize
the HGF activity. The colony number of the MDA-MB-468 cells
in the CAF #199C co-culture was significantly reduced to the
level similar to NAF #200N by the addition of 80 mg/ml of the
anti-HGF antibody (Figure 3A). However, the MDA-MB-468 cell
colony formation was not affected by the addition of antibodies
against TIMP-1. Also, the number of the MDA-MB-468 cell
colonies supported by NAF #200N was unaffected when an anti-
IGFBP-3 antibody up to the concentration of 80 mg/ml was added
(Figure 3B). Overall, our results suggested that HGF is the major
factor contributing to the differential effects of CAFs on cancer cell
colony forming ability.
Pre-coculture with breast cancer cells enhanced the
ability of NAFs to mediate cancer cell colony formation
and breast tumor growth
To test whether cancer cells instruct surrounding fibroblasts to
secrete factors such as HGF to promote tumor growth, we co-
cultured NAF #200N with MDA-MB-468 cells using a transwell
insert containing a 0.4-mm polyester membrane. In this co-culture
system, NAFs were grown on the bottom of the culture dish and
MDA-MB-468 cells were seeded on the membrane of the
transwell insert. After incubation for 3.5 days, NAF #200N was
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absence of MDA-MB-468 cells for further passages (indicated as
NAF #200N.E1 P.1, P.2 and P.3, respectively); or continued to
co-culture with MDA-MB-468 cells to generate NAF #200N.E2
(Figure 4A). Following this scheme, we also generated NAF
#200N.E3 and NAF #200N.E4. The HGF protein levels in NAF
Figure 1. Breast cancer-associated fibroblasts enhanced breast tumorigenesis to a higher level than normal tissue-associated
fibroblasts. (A) CAF/NAF pairs from the same patients were isolated and subjected to soft agar colony formation assay using MDA-MB-468 cells. For
each pair of fibroblasts examined, CAFs significantly enhanced colony forming ability of MDA-MB-468 cells to a higher level than NAFs. Data are mean
6 SD of triplicate samples. (B) The average of colony number of MDA-MB-468 cells mediated by CAFs and NAFs from all samples was shown. Data are
mean 6 SD. (C) For each pair of fibroblasts tested, CAFs enhanced soft agar colony forming ability of SK-BR-3 cells more effectively than NAFs. Data
are mean 6 SD of triplicate samples. (D) The average of SK-BR-3 cell colony numbers mediated by CAFs and NAFs from all samples was shown. Data
are mean 6 SD. (E) CAF #199C significantly enhanced tumor growth in the NOD/SCID fat pads than its normal counterpart NAF #200N and the
control (no fibroblasts). Tumor volume was determined every three days after injection. Data are mean 6 SEM of tumors from 6 mice. Statistical
significance between CAF #199C and NAF #200N was evaluated by Student’s t-test. * P,0.05.
doi:10.1371/journal.pone.0015313.g001
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increased, compared to those in NAF #200N when analyzed by
Western blotting (Figure S2). The HGF protein levels in NAF
#200N.E1 and E2 were reduced to the level of NAF #200N up to
the third passage in the absence of MDA-MB-468 cell co-culture
(Figure 4B). However, the HGF protein levels in NAF #200N.E3
P.3 and E4 P.3 were still higher than those in NAF #200N. The
HGF amounts secreted from NAF #200N.E3 P.3 and E4 P.3, but
not E1 P.3 and E2 P.3, were also higher than NAF #200N
(Figure 4C). These results indicated that co-culture with MDA-
MB-468 cells was sufficient to induce HGF protein secretion from
NAFs. However, stabilization of HGF induction required
prolonged co-culture since subcultures of NAF #200N.E1 and
E2 did not have a sustained elevated HGF protein level.
To examine whether NAFs, pre-cocultured with MDA-MB-468
cells, increase their capacities to support tumor growth, we
performed colony formation assays to evaluate the colony
formation promotion abilities of NAF #200N.E1-E4 P.4 com-
pared to NAF #200N. The results showed that NAF #200N.E4
P.4 exhibited higher promoting ability than NAF #200N
(Figure 4D). However, NAF #200N.E1-E3 P.4 did not signifi-
cantly increase the MDA-MB-468 cell colony formation than NAF
#200N. These results indicated that pre-coculture with MDA-
MB-468 cells for 4 passages, rather than 3 passages, stimulated
tumorigenic promoting ability of NAFs. HGF protein levels in
NAF #200N.E3 P.3 and E4 P.3 were both significantly higher
than NAF #200N. Thus, it is likely that the expression of HGF in
NAF #200N E3 P.3 cannot sustain to promote the MDA-MB-468
cell colony formation during the assay. Consistently, in breast
tumorigenesis analysis using the NOD/SCID mice, NAF
#200N.E4 P.4 significantly promoted the MDA-MB-468 tumor
growth compared to NAF #200N (Figure 4E). Taken together,
these results suggested that coculture with the breast cancer cells
could change the nature of NAFs to facilitate breast tumorigenesis.
Discussion
In this communication, we evaluated the differential contribu-
tion of CAFs and their counterpart NAFs derived from the same
breast cancer patients to breast tumorigenesis. We found that
CAFs had higher ability to promote breast cancer MDA-MB-468
cells to form colonies in soft agar and to facilitate tumor growth in
NOD/SCID mice than NAFs. By comparing the profiles of
proteins secreted from CAFs and NAFs using the cytokine/growth
factor antibody arrays, significantly higher levels of HGF and
TIMP-1 secreted from CAFs were revealed. The amount of HGF,
but not TIMP-1, from these fibroblasts was positively correlated
with their ability to enhance breast tumorigenesis. Conversely,
deprivation of HGF using a neutralizing antibody reduced CAF-
mediated colony formation of breast cancer cells, indicating that
CAFs enhanced cancer cell colony formation mainly through
HGF. Co-culturing NAFs with breast cancer cells in a transwell
system for several passages was able to enhance the ability of NAFs
to promote tumorigenicity as well as HGF expression to the
compatible level as that of CAFs. These results indicated that
breast cancer cells reprogram its surrounding fibroblasts to secrete
HGF, in part, to support its own progression via paracrine
signaling.
HGF secreted by fibroblasts has been shown to mediate
proliferation and invasion of cancer cells [12,13]. It has been
Figure 3. Sequestration of the HGF activity reduced cancer-
associated fibroblast-mediated soft agar colony formation of
MDA-MB-468 cells. (A) Neutralization of HGF activity by addition of
80 mg/ml anti-HGF antibody significantly reduced CAF #199C-mediated
soft agar colony formation of the MDA-MB-468 cells. However, the anti-
TIMP-1 antibody did not show any effect. (B) NAF #200N-mediated soft
agar colony formation of MDA-MB-468 cells was not affected by
addition of 80 mg/ml anti-IGFBP-3 antibody. Data are mean 6 SD of
three independent experiments. * P,0.05. NS, no significant difference.
doi:10.1371/journal.pone.0015313.g003
Figure 2. Breast cancer-associated fibroblasts expressed higher HGF levels than normal tissue-associated fibroblasts. (A) Regression
of the cytokine/growth factor signal intensities in the conditional media from CAF #199C and NAF #200N was performed to evaluate the difference
of the cytokines and growth factors secreted by CAFs and NAFs. The results revealed that HGF (4.57 fold) and TIMP-1 (1.41 fold) levels were
significantly higher in the conditional medium from CAFs than those in the conditional medium from NAFs (array B). In contrast, lower levels of GCP-2
(0.17 fold) (array A), IGFBP-3 (0.48 fold), GRO family (0.44 fold), GRO-a (0.6 fold), ENA-78 (0.63 fold), GCSF (0.54 fold) (array B) and LAP (0.59 fold) (array
C) were detected in the conditional media from CAFs compared to those in the conditional medium from NAFs. (B) Western blotting analysis revealed
that the HGF protein levels in CAFs were higher than those in NAFs in all fibroblast pairs (upper panel). Whereas, there was no correlation observed
between CAFs and IGFBP-3 protein expression (lower panel). (C) Enzyme-linked immunosorbent assay showed that the HGF amounts in the cultured
media of CAFs were higher than those of NAFs in all fibroblast pairs. (D) Quantitative real-time RT-PCR analysis showed that the HGF mRNA levels in
CAFs were higher than those in NAFs in all fibroblast pairs. (E) Real-time RT-PCR analysis revealed that the mRNA levels of SDF-1 a, SDF-1 b and SDF-1
c varied in different samples. There was no association between the SDF-1 mRNA levels and CAFs. Data are mean 6 SD of triplicate samples.
* P,0.05. NS, no significant difference.
doi:10.1371/journal.pone.0015313.g002
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fibroblasts [8,17]. Consistently, we found that HGF expression level
was extremely low in breast cancer MDA-MB-468 cells compared
to CAFs and NAFs (Figure S3). Ectopic expression of HGFin breast
fibroblasts was used to promote tumor initiation and growth of
human breast epithelial organoids in the humanized fat pads of
NOD/SCID mice [18,19]. Consistently, our data revealed that
HGF protein and mRNA levels in fibroblasts derived from the
breast cancer patients were positively correlated with their abilities
to enhance breast tumorigenesis. Neutralization of HGF activity
reduced CAF-mediated colony formation of breast cancer cells,
suggesting that HGF secreted by CAFs may be the major
contributing factor for this differential tumorigenic promoting
ability between CAFs and NAFs. Although TIMP-1 was the other
factor significantly elevated in CAF cells, deprivation of TIMP-1
activity did not affect cancer cell colony formation promoted by
CAFs (Figure 3A). It is likely that the soft agar colony assay system
may fail to address the contribution of TIMP-1 in tumorigenesis
because the main function of TIMP-1 is to inhibit activities of
matrix metalloproteinases (MMPs) [20]. Intriguingly, SDF-1
released by stroma fibroblasts has been reported as a major factor
contributing to breast tumorigenesis [10]. However, our data
Figure 4. Pre-coculture with breast cancer cells enhanced the ability of normal tissue-associated fibroblasts to mediate breast
tumorigenesis. (A) The protocol of the co-culture system using MDA-MB-468 cells and NAFs was shown. NAF #200N co-cultured with MDA-MB-468
cells for four passages was indicated as 200N.E1-E4, respectively. Each fibroblast of 200N.E1-E4 was propagated in the absence of MDA-MB-468 cell
co-culture and passaged from P.1 to P3. (B) The HGF protein expression in NAF #200N.E1-E4 was shown. The HGF protein levels in NAF #200N.E1
and E2 were reduced to the level in NAF #200N after three passages (P.3). However, the HGF protein levels in NAF #200N.E3 P.3 and E4 P.3 were
significantly higher than those in NAF #200N. (C) Enzyme-linked immunosorbent assay showed that the HGF protein amounts in the cultured media
of NAF #200N.E3 P.3 and E4 P.3, rather than E1 P.3 and E2 P.3, were higher than those of NAF #200N. (D) NAF #200N.E4 P.4 significantly enhanced
soft agar colony formation of MDA-MB-468 cells to a higher level than NAF #200N. For (B), (C) and (D), data are mean 6 SD of three independent
experiments. (E) NAF #200N.E4 P.4 significantly increased the tumor growth in the NOD-SCID fat pads compared to NAF #200N. Tumor volume was
determined every three days after injection. Data are mean 6 SEM of tumors from 4 mice. Difference between NAF #200N.E4/CAF #199C and NAF
#200N was evaluated by Student’s t-test. * P,0.05.
doi:10.1371/journal.pone.0015313.g004
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strictly correlated with theirabilitiesto mediate breast tumorigenesis
(Figure 2D), indicating that HGF, rather than SDF-1, is a common
contributing factor of CAFs in promoting tumorigenesis.
Based on the cytokine array assay, the levels of GCP-2, GRO-a,
ENA-78, IGFBP-3 and LAP secreted from CAFs were lower than
NAFs (Figure 2A). IGFBP-3 has been shown to be an invasion
suppressor [21]. Whether it plays a role in cancer cell proliferation
and tumor growth remains unclear. Our data suggested that
neutralizing IGFBP-3 activity did not affect cancer cell colony
formation promoted by NAFs (Figure 3B), indicating that IGFBP-
3 may not be the contributing factor in this soft agar assay system.
Similarly, blockage of GCP-2 activity did not affect NAF-mediated
colony formation of cancer cells (Figure S4), although GCP-2,
GRO-a and ENA-78 belong to the CXC chemokine family,
possibly involved in metastasis and tumor growth [22]. LAP is
known to be associated with transforming growth factor-beta
(TGF-b) to form a latent TGF-b complex [23], which is secreted
and activated by binding to latent TGF-beta binding protein
(LTBP). However, whether LAP plays a role in tumorigenesis
remains to be tested.
The differential effects derived from CAFs and NAFs suggest that
cancer cells have the ability to instruct their surrounding fibroblasts
to reprogram their expression profiles to support cancer cell growth.
To directly address this possibility, we used a transwell system to co-
culture NAFs with breast cancer cells to test how NAFs respond to
cancer cells. Using HGF as a common marker, it appeared that pre-
coculture with the breast cancer MDA-MB-468 cells increased and
maintained higher HGF protein levels in NAF #200N.E3 and E4
(Figure 4B and 4C). Importantly, high level of HGF in NAF #200N
E4 exhibited significantly higher ability to enhance cancer cell
colony formation than NAFs #200N. These results revealed a
process that cytokine factors secreted from breast cancer cells
inducedNAFstosecreteHGFinspiteofthosefactorswereremoved.
How breast cancer cells instruct their surrounding fibroblasts to
promote tumor progression is not fully understood. Platelet-
derived growth factor (PDGF), fibroblast growth factor 2 (FGF2)
and TGF-b released by cancer cells may be candidates to mediate
fibroblasts activation, but the previous data were not sufficient to
support this notion [9]. For example, TGF-b could play a role in
suppressing the ability of fibroblasts to mediate cancer initiation
[8,9]. Conditional inactivation of TGF-b type II receptor in
fibroblasts in mice was shown to induce epithelial cells in prostate
and fore stomach to malignancy, which may be regulated by
elevation of HGF secretion from fibroblasts [24]. These results
indicated that TGF-b signaling may suppress secretion of HGF
from fibroblasts to limit proliferation of adjacent epithelial cells in
normal condition. However, whether TGF-b signaling is blocked
in activated fibroblasts or not and how HGF or other factors
secreted by activated fibroblasts make epithelial cells to become
malignant remain to be elucidated. Nevertheless, the factors
secreted from co-cultured breast cancer cells via paracrine
signaling will induce the surrounding fibroblasts to change the
expression profiles. The fact that tumor promoting ability of
instructed fibroblasts remains even the factors from cancer cells
were removed, suggested a genome reprogramming in these
fibroblasts. The established co-culture system will allow us to
further dissect this reprogramming process.
Materials and Methods
Ethics statement
All human specimens were encoded to protect patient
confidentiality and processed under protocols approved by the
Institutional Reviews Board of Human Subjects Research Ethics
Committee of Academia Sinica (AS-IRB02-98042) and National
Taiwan University hospital (#200902001R), Taipei, Taiwan.
Breast cancer tissues and its relative normal counterparts were
obtained from patients who underwent surgery at National
Taiwan University Hospital. Signed consent for the studies was
obtained from all the patients.
Animal care and experiments were approved by the Institu-
tional Animal Care and Utilization Committee of Academia
Sinica (IACUC #080085).
Clinical specimens and cell cultures
All human breast cancer tissues and its relative normal
counterparts were minced to 2–3 mm
3 cubes and attached onto
the culture dishes for fibroblast culture. Primary fibroblast isolated
from clinical specimen were maintained in Dulbecco’s Modified
Eagle’s Medium/F-12 Nutrient Mixture (DMEM/F-12) (Invitro-
gen) supplemented with 10% fetal bovine serum (Industrial
Biological), 0.1 mM non-essential amino acids and 1 mM sodium
pyruvate (Invitrogen, above). Breast cancer cell lines, MDA-MB-
468 and SK-BR-3, were cultured in DMEM/F-12, supplemented
with 10% fetal bovine serum. Cells were incubated at 37uCi na
humidified incubator with 5% CO2.
Soft agar colony formation assay
2610
5 primary fibroblasts were seeded in a 35-mm culture dish
and cultured for 3–4 days to reach 100% confluent. Cells were
further incubated one more day before assay. After washed with
phosphate buffered saline twice, 1 ml of 0.5% agar in DMEM/F-
12 containing 2% fetal bovine serum was added on top of the
fibroblasts to form a base layer. For neutralization of cytokines and
growth factors, mouse anti-human HGF, anti-human TIMP-1 and
anti-human IGFBP-3 antibodies (R&D Systems) were added into
the medium and mixed with the agar. After the agar was solidified,
5000 MDA-MB-468 or SK-BR-3 cells were evenly suspended in
1 ml of 0.35% agar in DMEM/F-12 containing 2% fetal bovine
serum and then added into the dish to form a cancer cell layer.
Dishes were incubated in a humidified, 37uC, 5% CO2 incubator
until cell colonies appear obviously (11 days for MDA-MB-468
cells and 21 days for SK-BR-3 cells). Colonies were fixed with
0.05% Crystal violet solution and counted (diameter larger than
40 mm) under light microscopy.
Breast tumorigenesis assay in NOD/SCID mice
Five to six-week-old female immunocompromised NOD/LtSz-
scid mice (The Jackson Laboratory) were used for in vivo
tumorigenesis assay. 5610
4 MDA-MB-468 cells were mixed with
2.5610
5 CAFs/NAFs with passage number 4–6, and then mixed
with Matrigel matrix (BD Biosciences) before injected into the
fourth mammary fat pads of the mice. The tumors of the MDA-
MB-468 cells were examined and determined for the volume up to
two months. Mice were housed in a room maintained on a 12 h
light/dark cycle (light on at 6 a.m.) with food and water provided
ad libitum.
Cytokine/growth factor antibody array analysis
The conditional media from CAF #199C and NAF #200N,
whichcontain nofetalbovineserum,were collectedafterincubation
for 24 hours. The conditional media were further concentrated by
the centrifugal filter devices (Amicon Ultra-4, 3 k, Millipore) to 100-
foldconcentrated volume and then subjectedto the human cytokine
antibody arrays (G series 2000, RayBiotech). These arrays included
array G series 6 (array A), array G series 7 (array B) and array G
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medium was added to each cytokine antibody array to perform the
assay following manufacturer’s procedures.
Western blotting analysis
Fibroblasts were grown to 100% confluent and replaced with
fresh medium one day before protein extraction with radio-
immunoprecipitation assay (RIPA) buffer containing 50 mM Tris-
HCl (pH 7.4), 150 mM NaCl and 1% IGEPAL CA-630, 2 mM
EDTA and protease inhibitors with thorough homogenization.
Lysates were clarified by centrifugation and resolved by SDS-8%
PAGE with 30 mg of protein content. The proteins resolved by
SDS-PAGE were transferred to the PVDF membrane and
immunoblotted with antibodies including mouse monoclonal
anti-human HGF, anti-human IGFBP-3 (R&D Systems, above),
and anti-alpha tubulin (abcam) antibodies followed by a
horseradish peroxidase (HRP)-conjugated horse-anti-mouse IgG
antibody (Cell Signaling). Membrane was developed by reacting
with chemiluminescenct HRP substrate and exposed to BioSpec-
trumAC imaging system (Ultra-Violet Products).
Enzyme-linked immunosorbent assay
Fibroblasts were grown to 100% confluent and replaced with
fresh medium one day before assay. The cultured medium was
clarified by centrifugation at 3006 g for 5 min. 100 mlo f
supernatant was subjected to enzyme-linked immunosorbent assay
for HGF (RayBiotech) following the manufacturer’s instruction.
Quantitative real-time RT-PCR
Total RNA from fibroblasts was isolated using TRI reagent
(Ambion). Purified RNA (1 mg) was subjected to cDNA synthesis by
Superscript II reverse transcriptase (Invitrogen) in 20 ml of reaction
volume. Real-time RT-PCR analysis was performed using the ABI
PRISM 7000 sequence detection system with SYBER Green
method (Applied Biosystems) according to the manufacturer’s
instruction. The primers used in this assay were: HGF: 59-AGT
TGG CTA CTG CTC CCA AA- 39 and 59-TTC CAT GTT CTT
GTC CCA CA-39; SDF-1 a:5 9-TGAGAG CTC GCT TTG AGT
GA- 39 and 59-CAC CAGGAC CTT CTG TGG AT-39; SDF-1 b:
59-CTA GTC AAG TGC GTC CAC GA- 39 and 59-GGA CAC
ACC ACA GCA CAA AC-39; SDF-1 c:5 9-GTG CCC TTC AGA
TTG TAG CC- 39 and 59-GGG CAG CCT TTC TCT TCT TC-
39; the internal control, beta-actin: 59-ATC TGG CAC CAC ACC
TTCTACA-39 and 59-TCA CCGGAGTCC ATC ACGAT-39.
The amplification mixture contained 1 mlo f5 6 diluted reverse
transcription product, 200 nM of each primer, 250 nM probe, and
12.5 mlo f2 6SYBER Green PCR master mix (Applied Biosystems)
in a total of 20-ml reaction volume. The thermal conditions were:
2 minat50uCand10 minat95uCfollowedby40cyclesat95uCfor
15 sec and 55uC for 1 min. The relative quantity of mRNA was
estimated by using a standard curve created by serial dilution of the
reverse transcription products from NAFs. Semi-quantitative
analysis of the HGF gene expression was normalized to that of
the beta actin gene expression.
Co-culture of fibroblasts with cancer cells
In the co-culture system, 8610
4 NAF #200N P.7 were grown in
the bottom of a 6-wellplate in 2.5 ml of DMEM/F-12 with 10% fetal
bovine serum and 1610
5 MDA-MB-468 cells were seeded on the
0.4-mm polyester membrane of a transwell insert (Corning) in 1.5 ml
of the same medium. Dishes were incubated in a humidified, 37uC,
5% CO2incubator. NAF #200N.E1 was derived after incubation for
78 hours. Some of NAF #200N.E1 fibroblasts were subcultured and
grown for generation of P.1, P.2 and P.3 without MDA-MB-468 cell
co-culture; others were subcultured and continued to co-culture with
MDA-MB-468 cells to generate NAF #200N.E2 after 78 hours.
Following the same procedure, NAF #200N.E3 and NAF
#200N.E4 were obtained, and all the fibroblasts with passage
number P.1, P.2 and P.3 were also generated.
Supporting Information
Figure S1 Cytokine/growth factor antibody array anal-
ysis of the conditional media from CAFs and NAFs. Image
of the cytokine/growth factor antibody array revealed that HGF
and TIMP-1 levels were significantly higher in the conditional
medium from CAF #199C than those in the conditional medium
from NAF #200N (array B). In contrast, lower levels of GCP-2
(array A), IGFBP-3, GRO family, GRO-a, ENA-78, GCSF (array
B) and LAP (array C) were detected in the conditional media from
CAF #199C compared to those in the conditional medium from
NAF #200N. The identical levels of MCP-1, IGFBP-6 and IGF-II
were used as the internal control for each array.
(TIF)
Figure S2 Co-culture with breast cancer MDA-MB-468
cells enhanced the HGF protein expression in NAFs.
Western blotting analysis revealed that the HGF protein levels in
MDA-MB-468 cell-cocultured NAF #200N.E1-E4 were higher
than NAF #200N. Data are mean 6 SD of three independent
experiments.
(TIF)
Figure S3 Breast cancer MDA-MB-468 cells expressed
low level of HGF. Real-time RT-PCR analysis showed that
HGF expression in MDA-MB-468 cells was extremely low
compared to CAF #199C and NAF #200N. Data are mean 6
SD of triplicate samples. * P,0.05. *** P,0.001.
(TIF)
Figure S4 Sequestration of the GCP-2 activity did not
affect NAF-mediated soft agar colony formation of the
breast cancer MDA-MB-468 cells. NAF #200N-mediated
soft agar colony formation of MDA-MB-468 cells was not affected
by addition of 80 mg/ml anti-GCP-2 antibody. Data are mean 6
SD of triplicate samples. * P,0.05. NS, no significant difference.
(TIF)
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